Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Cogent Biosciences (COGT) EBT Margin (2017 - 2020)

Cogent Biosciences' EBT Margin history spans 4 years, with the latest figure at 18325.64% for Q3 2020.

  • Quarterly EBT Margin fell 1714868.0% to 18325.64% in Q3 2020 from the year-ago period, while the trailing twelve-month figure was 1042.5% through Dec 2020, down 90066.0% year-over-year, with the annual reading at 1042.5% for FY2020, 90066.0% down from the prior year.
  • EBT Margin came in at 18325.64% for Q3 2020, down from 1401.52% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 15.05% in Q4 2019 to a low of 18325.64% in Q3 2020.
  • The 4-year median for EBT Margin is 327.26% (2017), against an average of 1634.34%.
  • The largest YoY upside for EBT Margin was 29626bps in 2020 against a maximum downside of -1714868bps in 2020.
  • Cogent Biosciences' EBT Margin stood at 319.41% in 2017, then rose by 29bps to 225.91% in 2018, then skyrocketed by 107bps to 15.05% in 2019, then tumbled by -121857bps to 18325.64% in 2020.
  • Per Business Quant, the three most recent readings for COGT's EBT Margin are 18325.64% (Q3 2020), 1401.52% (Q2 2020), and 86.67% (Q1 2020).